Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in cancer
Helen M. Coley(University of Surrey), Nelofer Syed(Hammersmith Hospital), Tim Crook(Bupa Cromwell Hospital), Iain A. McNeish(Imperial College London), Alastair Thompson(University of Dundee), Sarah P. Blagden(Churchill Hospital), Eleftheria Hatzimichael(Thomas Jefferson University)
Cited by 33
Related Papers
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
The p53 pathway in breast cancer
|Breast Cancer Research|2002|396